Significant lightening outcomes become noticeable after 3 to 4 weeks as the skin regenerates
GLP-1R agonists have been approved for the treatment of T2DM since 2005, but it was only with the approval of tirzepatide (a dual GLP-1R/GIPR agonist) in 2022 that a drug acting on GIPR was used clinically (Willard et al., 2020)
Their approach emphasizes accessibility and convenience
After full recovery, correct cannulation was tested by observing water drinking responsiveness after infusion of 1 l human angiotensin II (Sigma-Aldrich, A9525) at a concentration of 24 M in artificial cerebrospinal fluid (distilled water with 125 mM NaCl, 2.5 mM KCl, 2.6 mM NaHCO 3 , 1.25 mM NaH 2 PO 4 2H 2 O, 25 mM d-glucose monohydrate, 1 mM MgCl 2 , 2 mM CaCl 2 )
This signal is mediated through mTOR pathway activation, mechanical tension on muscle fibers, and metabolic stress
doi: 10.1038/s41380-022-01792-4